- Swallowed peptides get under 1% of the dose into your bloodstream. Even Rybelsus, with Novo Nordisk's full engineering behind it, manages 0.4 to 1%.
- Injected peptides deliver 75 to 100%, because injection skips all three of the digestive barriers that destroy the oral version.
- BPC-157 genuinely survives stomach acid for over 24 hours in the lab. Whether any of it then crosses into your bloodstream has never been measured in a human.
- Topical GHK-Cu is measured in micrograms delivered per square centimetre of skin, not in percentages. The researchers who measured it concluded useful amounts of copper get in. It still works at the skin, not deeper.
- Injecting under the skin and into muscle both get nearly everything in. The difference is timing: muscle peaks faster, under the skin releases more steadily.
Oral semaglutide, the drug that launched a thousand copycat compounds, achieves 0.4 to 1% bioavailability. Novo Nordisk spent years and billions of dollars engineering it to survive the human stomach. They solved the problem partially using a synthetic absorption enhancer called SNAC, patented the formulation, and still ended up with 99% of every dose destroyed before it reaches your blood. That is the state of the art for oral peptides in 2026.
Oral bioavailability of semaglutide (Rybelsus), the most heavily engineered oral peptide on the market. Injected under the skin (Ozempic), the same molecule reaches roughly 89%. Same drug, different route, roughly a hundredfold difference.
For the research peptides most people are actually running (BPC-157, ipamorelin, GHK-Cu, TB-500), the situation is more complicated than "oral bad, injectable good." Each route has a specific mechanism, a specific ceiling, and a specific use case. The route you pick determines how much of what you paid for actually reaches your tissues. This article gives you the numbers on all three.
Why Do 99% of Oral Peptides Never Reach Your Blood?
Three sequential barriers destroy nearly every peptide you swallow. Not one. Three. Any peptide that survives the first two still faces a third. Getting through all three at meaningful concentration is the problem no oral formulator has fully solved, even with pharmaceutical-grade engineering.
Your stomach runs at pH 1 to 2, optimized for the enzyme pepsin. Pepsin cleaves peptide bonds at aromatic amino acids: phenylalanine, tyrosine, tryptophan. Most therapeutic peptides contain at least one of these residues. Exposure time in an average stomach is 30 to 120 minutes. That is long enough to fragment most peptides into non-functional pieces before they reach the small intestine.
If a peptide survives the stomach, it enters the small intestine where four more enzymes wait: trypsin, chymotrypsin, elastase, and carboxypeptidase. These target different peptide bonds than pepsin, so a fragment that pepsin missed is usually caught here. Brush-border membrane enzymes at the intestinal surface then attack anything that reaches the epithelial layer.
Peptides above roughly 1 kDa face near-zero passive diffusion across the intestinal epithelium. The gut wall evolved to absorb amino acids and small di-peptides, not intact therapeutic peptides of 10 to 50 amino acids. Anything that slips through the epithelial cells enters the portal vein and goes to the liver first, where a second round of degradation runs before the compound reaches systemic circulation.
Every oral peptide that has made it through regulatory approval lands in the same place: under 1% of the swallowed dose reaching the bloodstream. Octreotide, with a chemical absorption enhancer built into the capsule, gets to roughly 0.7%. Semaglutide, with a different enhancer and years of formulation work, gets to 0.4 to 1%. Those are the best results the pharmaceutical industry has produced, with resources no supplement company has.
Think of your digestive system as a nightclub with three bouncers at three different doors. The first (stomach acid) checks your chemical structure. The second (intestinal enzymes) rechecks anyone who got past the first. The third (the gut wall and then the liver) blocks anything too large or too obviously a foreign protein. A peptide drug has to get past all three. Most do not make it past the first door.
BPC-157 Is the Exception. Here Is What That Actually Means.
BPC-157 (body protection compound-157) is a 15-amino-acid peptide originally isolated from human gastric juice. That origin matters: it was found in stomach acid, which means it evolved under pressure to survive that environment. In laboratory conditions it resists pepsin for more than 24 hours. That is genuinely unusual. Most therapeutic peptides come apart within minutes under the same conditions.
That makes oral BPC-157 plausible for effects on the gut itself. Animal work has repeatedly shown healing and protection along the gut wall after oral dosing. If your goal is gut-lining repair, the oral route may put the peptide directly onto the tissue you want repaired, without ever needing it to reach the bloodstream.
The critical distinction: surviving the stomach is not the same as reaching your bloodstream. No published human pharmacokinetic study has measured systemic BPC-157 concentration after oral dosing. Animal models confirm gut-healing effects from oral administration. Whether oral BPC-157 reaches systemic circulation at therapeutic levels for tendon repair or systemic anti-inflammatory goals is not answered in the indexed literature. If your goal is gut healing, oral may be the right route. If your goal is tendon or ligament repair, the evidence supports injection. See the full breakdown of who responds to BPC-157 and who does not. The complete mechanism and dosing data is on the BPC-157 peptide page.
Injectable Delivers 75 to 100%: What Changes Between Subcutaneous and IM?
Injectable peptides bypass all three GI barriers completely. Neither your stomach, your intestinal enzymes, nor your liver process the compound before it enters systemic circulation. Subcutaneous and intramuscular injections both achieve 75 to 100% bioavailability for most peptides. The difference between them is not how much gets in. It is how fast and how consistently it arrives.
| Factor | Subcutaneous | Intramuscular |
|---|---|---|
| Bioavailability | 75-100% | 75-100% |
| Time to peak (Tmax) | Slower (minutes to hours) | Faster (30-60 min typical) |
| Release profile | Sustained, stable plasma levels | Higher initial peak, faster fall |
| Best for | GH secretagogues, repair peptides, daily protocols | Acute protocols, faster-acting compounds |
| Needle | 27-31 gauge, half-inch | 22-25 gauge, 1 to 1.5 inch |
For GH secretagogues like ipamorelin and CJC-1295, subcutaneous is the preferred route. The goal is to mimic the body's natural pulsatile GH release pattern, which means a slow, predictable absorption curve matters more than a high fast peak. For more on the injection errors that undermine that timing, the peptide dosing guide covers the most common protocol mistakes.
IM injection delivers compound into highly vascularized muscle tissue. Blood flow in muscle is higher than in subcutaneous fat, producing faster peak concentrations. For insulin, IM peaks at roughly 60 minutes versus 90 minutes subcutaneously. For most research peptides, the kinetic difference matters clinically only when you need a fast local or systemic effect. Tissue repair protocols generally benefit more from the sustained subcutaneous release profile.
Bioavailability of semaglutide injected under the skin (Ozempic), against 0.4 to 1% for the same drug swallowed (Rybelsus). A 2025 meta-analysis (Karedath, Cureus, PMID 40385819) found the oral version also carried a 79% higher rate of people stopping treatment because of digestive side effects.
Do Topical Peptides Actually Penetrate Skin?
You will see percentages quoted for this all over the internet. They are not in the source. The work that actually measured GHK-Cu crossing human skin is Hostynek and colleagues (PMID 20703511 and PMID 20721598), who used diffusion cells and reported their results the way skin researchers do: micrograms of copper delivered per square centimetre of skin, not a percentage of the bottle. Their conclusion was that topical application delivers copper into skin in amounts large enough to matter therapeutically.
That is a more useful framing than a percentage anyway, because a percentage of an applied dose tells you nothing without knowing how much was applied over how much area for how long. If someone quotes you a headline percentage for topical peptide absorption, ask which paper it came from. Usually there is not one.
What the measurement does not tell you is how deep the peptide travels. The outermost layer of skin, the stratum corneum, is a wall of dead flattened cells built specifically to stop things getting through, and it holds most of what you apply. That is where topical GHK-Cu concentrates, and it is also where the collagen support and wrinkle work it is sold for is supposed to happen. For realistic timelines and what the before-and-after data shows, see the GHK-Cu before and after breakdown.
Many commercial serums use a version with a fatty acid chain attached (palmitoyl-GHK) on the theory that a greasier molecule moves more easily through a greasy barrier. The theory is sound. The comparative numbers you will see quoted for it are not traceable to a published head-to-head study.
When Topicals Do Not Work
Topical peptides work when the target is the skin. They do not work for anything systemic. Topical BPC-157 will not heal your tendon. GHK-Cu serum will not raise the amount of copper peptide circulating in your blood. The barrier that limits delivery is the same one that stops you absorbing everything your skin touches, which on balance you want.
People with the skin-barrier conditions that run in families, eczema in particular, have a leakier outer layer and absorb topical compounds more readily, along with more irritation from concentrated products. That is worth knowing before you apply a strong serum. Nobody has measured how much it changes peptide absorption specifically.
How the FDA Got Oral Peptides to Work (And What Engineering It Required)
Three oral peptide drugs now hold FDA approval. Each required a different engineering approach to get past the three digestive barriers. None of them ended up with injectable-level bioavailability.
| Drug | Peptide | Approved | Technology | Bioavailability |
|---|---|---|---|---|
| Rybelsus | Semaglutide (GLP-1) | 2019 (T2D), 2025 (CV) | SNAC absorption enhancer | 0.4 to 1% |
| Mycapssa | Octreotide | 2020 | Sodium caprylate | 0.7% |
| Icotyde | Icotrokinra (IL-23 antagonist) | March 2026 | Cyclic peptide structure | Not published |
The SNAC approach used in Rybelsus is instructive. SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) creates a high-pH microenvironment in the stomach that temporarily suppresses pepsin activity and fluidizes the epithelial membrane in a narrow local zone around the tablet. The drug has approximately 30 minutes to be absorbed through that window before stomach mixing disperses the SNAC. This is why Rybelsus must be taken on an empty stomach with no more than four ounces of water, 30 minutes before anything else. Disrupt that microenvironment and bioavailability drops further still.
The result after all that engineering: 0.4 to 1%. A 2025 meta-analysis by Karedath in Cureus (PMID 40385819) found that at equivalent doses, injected semaglutide lowered long-term blood sugar (HbA1c) more than the oral version did, and that people on the oral version were 79% more likely to stop treatment because of digestive side effects. The engineering partly solved the absorption problem. It did not solve the side effects that come from pushing the dose up to compensate.
Icotyde (icotrokinra), approved by FDA in March 2026 for plaque psoriasis, takes a structurally different approach: a cyclic peptide backbone that is inherently more resistant to proteolytic enzymes than linear peptides. J&J described it as the first targeted oral peptide in its drug class. The cyclic structure limits the enzyme's ability to find and cleave the vulnerable bond. This design-level solution is more elegant than the absorption-enhancer approach, and it represents where oral peptide technology is heading. Whether similar cyclic peptide design reaches research-grade compounds in the next decade is an open question.
How to Match Your Delivery Route to Your Goal
The question is not which route is objectively best. It is which route fits what you are trying to accomplish. Here is the practical decision tree the existing content almost never lays out clearly.
Choose oral if your primary goal is gut lining repair, mucosal healing, or GI inflammation. BPC-157's acid stability makes oral a plausible route for GI-targeted effects. For any other peptide with a systemic goal, the bioavailability data does not support oral as your primary route. You are delivering under 1% at best.
The right choice for BPC-157 tendon repair, GH secretagogues (ipamorelin, CJC-1295), Epithalon, MOTS-c, and any peptide where you need sustained systemic levels. Subcutaneous gives stable plasma levels, easy administration, and near-complete bioavailability. Most research peptide protocols default here for good reason.
GHK-Cu, palmitoylated cosmetic peptides, and copper peptide serums work at the skin surface layer. If your goal is collagen support, wrinkle reduction, or wound healing at skin level, topical is the right and sufficient route. Do not expect systemic anti-aging effects from topical application of any current peptide formulation.
One thing this article deliberately does not do is tell you your genes change the right route. No published clinical study has linked any variant to meaningfully different peptide absorption by any route, and the numbers above apply to essentially everybody. The hundredfold gap between swallowing and injecting dwarfs any individual variation anyone has found.
Where genetics does earn its place is one step earlier: not how to get a peptide in, but which peptides are worth getting in at all. That is what the PeptidesDNA report is for.
Frequently asked questions
Can you take BPC-157 orally?
BPC-157 is one of the only research peptides that genuinely survives stomach acid for over 24 hours in lab conditions. This makes oral administration plausible for gut-local effects like mucosal healing and gut lining repair. However, no published human study has measured systemic BPC-157 levels after oral dosing, so for tendon repair or systemic anti-inflammatory effects, injection remains the evidence-supported route.
Does oral BPC-157 work for tendon healing?
The published animal model evidence for BPC-157 tendon healing comes primarily from injection protocols, not oral administration. BPC-157 survives stomach acid unusually well for a peptide, but there is no human pharmacokinetic data showing it reaches systemic circulation at therapeutic concentrations after oral dosing. If tendon or ligament repair is your goal, subcutaneous injection is the route with documented evidence behind it.
Do topical peptides like GHK-Cu actually work?
Yes, at the skin. The researchers who actually measured GHK-Cu crossing human skin (Hostynek and colleagues, PMID 20703511) reported delivery in micrograms of copper per square centimetre and concluded that useful amounts get in. The percentages you see quoted online do not come from that work or any other. What is clear is that the peptide concentrates in the outer skin layers, which is where the collagen and wrinkle effects are meant to happen, and that it will not produce anything systemic.
Why does oral semaglutide work if peptides have less than 1% bioavailability?
Because the dose is calibrated around that 0.4 to 1%. You swallow 7 to 14 mg to reach blood levels an injection achieves with a fraction of that. The tablet carries SNAC, a patented absorption enhancer that briefly suppresses stomach enzymes and loosens the gut wall for a short window. Even so, the injected version lowers long-term blood sugar more, and a 2025 meta-analysis found the oral version had a 79% higher rate of people stopping because of digestive side effects.
Does subcutaneous or intramuscular injection work better for peptides?
Both routes achieve 75 to 100% bioavailability for most peptides, so neither is superior on that metric. Subcutaneous injection gives slower, more sustained plasma levels, which suits protocols that want steady exposure like GH secretagogues and BPC-157 for tissue repair. Intramuscular injection produces faster peak concentrations, which suits acute applications where speed matters. Most research peptide protocols default to subcutaneous because the sustained release profile fits most goals better.
Can intranasal peptide delivery work as an alternative to injection?
Intranasal delivery bypasses first-pass liver metabolism and can achieve meaningful bioavailability for small peptides via the nasal mucosa. Selank and Semax are commonly administered intranasally in Russian clinical protocols, and the pharmacokinetics support this route for those specific compounds. BPC-157 intranasal use exists in practice but has no published human pharmacokinetic data for this route. The nasal mucosa is more permeable than gut epithelium but offers a smaller absorption surface area, which limits total dose delivery per administration.
How does my genetics affect which delivery route works best for me?
As far as anyone has published, it does not. No clinical study has linked a genetic variant to meaningfully different peptide absorption by any route, and the hundredfold gap between swallowing and injecting swamps any individual difference that has been proposed. Genetics is useful one step earlier, in deciding which peptides are worth taking at all.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.